JP2012500018A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012500018A5 JP2012500018A5 JP2011523457A JP2011523457A JP2012500018A5 JP 2012500018 A5 JP2012500018 A5 JP 2012500018A5 JP 2011523457 A JP2011523457 A JP 2011523457A JP 2011523457 A JP2011523457 A JP 2011523457A JP 2012500018 A5 JP2012500018 A5 JP 2012500018A5
- Authority
- JP
- Japan
- Prior art keywords
- egf
- seq
- amino acid
- sequence
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0815264.7A GB0815264D0 (en) | 2008-08-21 | 2008-08-21 | Non-cytotoxic proteins |
| GB0815264.7 | 2008-08-21 | ||
| PCT/GB2009/051036 WO2010020811A1 (en) | 2008-08-21 | 2009-08-19 | Non-cytotoxic fusion proteins comprising egf muteins |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012500018A JP2012500018A (ja) | 2012-01-05 |
| JP2012500018A5 true JP2012500018A5 (https=) | 2014-08-07 |
| JP5658152B2 JP5658152B2 (ja) | 2015-01-21 |
Family
ID=39812369
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011523457A Expired - Fee Related JP5658152B2 (ja) | 2008-08-21 | 2009-08-19 | 非細胞毒性融合タンパク質 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8614069B2 (https=) |
| EP (1) | EP2326665B1 (https=) |
| JP (1) | JP5658152B2 (https=) |
| DK (1) | DK2326665T3 (https=) |
| ES (1) | ES2436816T3 (https=) |
| GB (1) | GB0815264D0 (https=) |
| PL (1) | PL2326665T3 (https=) |
| PT (1) | PT2326665E (https=) |
| WO (1) | WO2010020811A1 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9617671D0 (en) * | 1996-08-23 | 1996-10-02 | Microbiological Res Authority | Recombinant toxin fragments |
| US8790897B2 (en) * | 1998-08-25 | 2014-07-29 | Syntaxin Ltd. | Treatment of mucus hypersecretion |
| JP5799397B2 (ja) | 2008-06-12 | 2015-10-28 | イプセン・バイオイノベーション・リミテッドＩｐｓｅｎ Ｂｉｏｉｎｎｏｖａｔｉｏｎ Ｌｉｍｉｔｅｄ | 癌の抑制 |
| AU2011323832B2 (en) * | 2010-10-25 | 2016-06-02 | Niiki Pharma Inc. | Method of treating neuroendocrine tumors |
| KR101519118B1 (ko) * | 2013-07-23 | 2015-05-12 | (주)피앤피바이오팜 | 고안정성 상피세포 성장인자 변이체 |
| WO2016156468A1 (en) | 2015-03-31 | 2016-10-06 | Vhsquared Limited | Polypeptides |
| HK1250011A1 (zh) * | 2015-03-31 | 2018-11-23 | Sorriso Pharmaceuticals, Inc. | 具有蛋白酶可切割接头的肽构建体 |
| DK3277719T3 (da) | 2015-03-31 | 2022-05-02 | Sorriso Pharmaceuticals Inc | Polypeptider |
| TW201814045A (zh) | 2016-09-16 | 2018-04-16 | 英商艾普森生物製藥有限公司 | 製造雙鏈梭狀芽孢桿菌神經毒素之方法 |
| WO2018060351A1 (en) | 2016-09-29 | 2018-04-05 | Ipsen Biopharm Limited | Hybrid neurotoxins |
| EP3519438A1 (en) | 2016-09-30 | 2019-08-07 | VHsquared Limited | Compositions |
| EP3312290A1 (en) | 2016-10-18 | 2018-04-25 | Ipsen Biopharm Limited | Cellular vamp cleavage assay |
| US11241480B2 (en) * | 2017-01-26 | 2022-02-08 | Washington University | Methods for modulation of dietary and microbial exposure with compositions comprising an EGFR ligand |
| UA128185C2 (uk) | 2018-01-29 | 2024-05-01 | Іпсен Біофарм Лімітед | Ботулінічний нейротоксин, який розщеплює ненейронний snare |
| GB201815817D0 (en) * | 2018-09-28 | 2018-11-14 | Ispen Biopharm Ltd | Clostridial neurotoxins comprising and exogenous activation loop |
| GB201900621D0 (en) * | 2019-01-16 | 2019-03-06 | Ipsen Biopharm Ltd | Labelled polypeptides |
| WO2020219599A1 (en) * | 2019-04-23 | 2020-10-29 | Aurora Oncology | Compositions and methods for treatment of distentable tissues |
| KR20220063148A (ko) | 2019-06-21 | 2022-05-17 | 소리소 파마슈티컬스 인크. | 조성물 |
| WO2020254827A1 (en) | 2019-06-21 | 2020-12-24 | Vhsquared Limited | Polypeptides |
| JP7680377B2 (ja) | 2019-06-21 | 2025-05-20 | ソリッソ ファーマシューティカルズ，インク． | ポリペプチド |
| WO2024249812A2 (en) * | 2023-06-01 | 2024-12-05 | Blaze Bioscience, Inc. | Egf variants and methods of use thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8003A (en) * | 1851-03-25 | Improvement in scythe-tastenings | ||
| GB9818548D0 (en) * | 1998-08-25 | 1998-10-21 | Microbiological Res Authority | Treatment of mucas hypersecretion |
| US8790897B2 (en) * | 1998-08-25 | 2014-07-29 | Syntaxin Ltd. | Treatment of mucus hypersecretion |
| US20080038274A1 (en) * | 1999-09-23 | 2008-02-14 | Foster Keith A | Inhibition of secretion from non-neuronal cells |
| US7037504B2 (en) | 2001-10-23 | 2006-05-02 | Waratah Pharmaceuticals, Inc. | Epidermal growth factor protein and gene, and methods of use therefor |
| EP1479693A4 (en) | 2002-02-05 | 2005-07-27 | Japan Science & Tech Agency | EGF / EGFR COMPLEX |
| WO2007109673A2 (en) * | 2006-03-20 | 2007-09-27 | Stanford University | Mutant epidermal growth factor polypeptides, nucleic acids, and uses therefor |
| GB0725321D0 (en) | 2007-12-31 | 2008-02-06 | Syntaxin Ltd | Delivery vehicles |
-
2008
- 2008-08-21 GB GBGB0815264.7A patent/GB0815264D0/en not_active Ceased
-
2009
- 2009-08-19 WO PCT/GB2009/051036 patent/WO2010020811A1/en not_active Ceased
- 2009-08-19 ES ES09785502.7T patent/ES2436816T3/es active Active
- 2009-08-19 JP JP2011523457A patent/JP5658152B2/ja not_active Expired - Fee Related
- 2009-08-19 PT PT97855027T patent/PT2326665E/pt unknown
- 2009-08-19 DK DK09785502.7T patent/DK2326665T3/da active
- 2009-08-19 PL PL09785502T patent/PL2326665T3/pl unknown
- 2009-08-19 EP EP09785502.7A patent/EP2326665B1/en active Active
- 2009-08-19 US US13/059,695 patent/US8614069B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5658152B2 (ja) | 非細胞毒性融合タンパク質 | |
| JP2012500018A5 (https=) | ||
| US10744190B2 (en) | Method for suppressing spasmodic torticollis | |
| CA2727082C (en) | Fusion proteins for use in suppression of acromegaly | |
| JP6050330B2 (ja) | 治療用融合タンパク質 | |
| US8796216B2 (en) | Suppression of neuroendocrine diseases | |
| JP2012518403A5 (https=) | ||
| US20150353908A1 (en) | Therapeutics for suppressing osteoporosis | |
| JP2020039349A (ja) | かゆみの抑制 | |
| JP2025532862A (ja) | 活性化外因性プロテアーゼ切断部位を含むクロストリジウム神経毒 | |
| JP2024510786A (ja) | 外来性の活性化ループを含むクロストリジウム神経毒素 | |
| AU2014200449B2 (en) | Suppression of neuroendocrine diseases | |
| JP2025534299A (ja) | 活性化エンドソームプロテアーゼ切断部位を含むクロストリジウム神経毒 | |
| HK40020225A (en) | Suppression of neuroendocrine diseases | |
| HK1154512A (en) | Fusion proteins for use in the treatment of acromegaly | |
| HK1154512B (en) | Fusion proteins for use in the treatment of acromegaly | |
| HK1190946A (en) | Fusion proteins for use in the treatment of acromegaly |